MedTrace Logo

The 90% Effective Sedation Dose Of Midazolam

NCT03813043 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-01-23

No results posted yet for this study

Summary

There are no clear conclusive clinical reports defining the adequate effective dose of midazolam in patients undergoing day-case esophageal-gastro-duodenoscopy (EGD). Defining such dosage will facilitate practitioners who are not anesthesia professionals to administer sedative drugs to establish a satisfactory level of moderate sedation. Our first aim is to determine the effective dose for 90% of patients (ED 90) of midazolam undergoing day-case EGD.

Conditions

  • Gastro-Esophageal Reflux Disease With Ulceration

Interventions

DRUG

Midazolam injection

Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)

Sponsors & Collaborators

  • King Fahad Specialist Hospital Dammam

    lead OTHER

Principal Investigators

  • Ahed zeidan, MD · King Fahad Specialist Hospital Dammam

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2019-11-15
Completion
2019-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03813043 on ClinicalTrials.gov